The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats by Michaela Lang (117542)

“…Riociguat significantly decreased RV hypertrophy (RVH) (0.55±0.02, <em>p</em><0.05), increased cardiac output (60.8±.8 mL/minute, <em>p</em><0.05) and decreased total pulmonary resistance (4.03±0.3 mmHg min⁻¹ ml⁻¹ 100 g BW, <em>p</em><0.05), compared with sildenafil and vehicle. …”

The response of the system with positive or mutually activating interactions between cAMP and calcium. by Fernando Siso-Nadal (369710)

“…<p>a A bifurcation diagram for calcium as a function of activated PLC when activated AC is at 0.17 M. …”

Influence of the inhibitory noise level <i>σ</i>. by Matthias S. Keil (93694)

“…<p>(<b>a</b>)The figure illustrates how an increase of the inhibitory noise level from <i>σ</i> = 0.25 to <i>σ</i> = 0.50 moves the maximum of <i>n-ψ</i> towards <i>t</i>_<i>c</i> = 500ms, thus <i>t</i>_rel (= the remaining time to collision after the peak) decreases from 133ms to 80ms. …”

Whole-brain GMV was compared between abstainers, relapsers and HCs using SPM8 plus DAREL analysis. by Junkai Wang (3092706)

“…<p>(A) VBM differences reflect decreased GMV in the left cuneus in abstainers compared with HCs; (B) VBM differences reflect decreased GMV in the bilateral cuneus and the right precuneus in relapsers compared with HCs. …”

Interpretation and characteristics of spatiotemporal (ST) images. by Shigeta Arichika (483606)

“…Dark tail velocity was calculated as the slope of the red line placed halfway between white and dark bands. As velocity decreased, the slope steepened. (C) An ST image of a vessel without a dark tail. …”

Dynamic Volume Changes in Astrocytes Are an Intrinsic Phenomenon Mediated by Bicarbonate Ion Flux by Clare M. Florence (115903)

“…Astrocyte shrinkage from GABA_A channel activation was significantly decreased to −5.0±0.6% of control in the presence of the membrane-permeant CA inhibitor acetazolamide (ACTZ). …”

Genotype.xlsx by Xianglai Liu (10989228)

“…</p> <p><b>Results:</b> We observed that AG genotype of rs1107592, AG genotype of rs4976976, and CA genotype of rs67756423 decreased the susceptibility to SCZ (<i>p </i>< 0.05). …”

Fig 3 - by Bettina C. Schwab (9515382)

“…(C) Response onset latencies of VLa decreases (purple) lead GPi increases (blue) by a median of 46 ms (**<i>p</i> = 0.01 rank sum test). …”

FABP4 and omentin-1 gene expression in epicardial adipose tissue from coronary artery disease patients by Valentina V. Miroshnikova (12680216)

“…EAT FABP4 mRNA level was decreased in obese CAD patients when compared to obese NCAD individuals (p=0.001). …”

In vitro antimicrobial activity of methanolic extracts from cutaneous secretions of Amazonian amphibians against phytopathogens of agricultural interest by Livia Deice RAASCH-FERNANDES (12794729)

“…The R. marina extract decreased the mycelial growth of C. truncatum at the concentration of 0.5 mg mL-¹, and inhibited the mycelial growth of A. flavus at concentrations of 0.1 and 0.5 mg mL-¹, which was similar to the inhibition by the positive control. …”

Table 2_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

“…The levels of cryoglobulin were also decreased following treatment (MD = −0.53, 95%CI: −0.80, −0.26), both at 6-month (MD = −0.67, 95%CI: −0.99, −0.35) and 12-month (MD = −0.67, 95%CI: −1.15, −0.19) follow-ups. …”

Table 4_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

“…The levels of cryoglobulin were also decreased following treatment (MD = −0.53, 95%CI: −0.80, −0.26), both at 6-month (MD = −0.67, 95%CI: −0.99, −0.35) and 12-month (MD = −0.67, 95%CI: −1.15, −0.19) follow-ups. …”

Supplementary file 1_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

“…The levels of cryoglobulin were also decreased following treatment (MD = −0.53, 95%CI: −0.80, −0.26), both at 6-month (MD = −0.67, 95%CI: −0.99, −0.35) and 12-month (MD = −0.67, 95%CI: −1.15, −0.19) follow-ups. …”

Table 1_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

“…The levels of cryoglobulin were also decreased following treatment (MD = −0.53, 95%CI: −0.80, −0.26), both at 6-month (MD = −0.67, 95%CI: −0.99, −0.35) and 12-month (MD = −0.67, 95%CI: −1.15, −0.19) follow-ups. …”

Table 3_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

“…The levels of cryoglobulin were also decreased following treatment (MD = −0.53, 95%CI: −0.80, −0.26), both at 6-month (MD = −0.67, 95%CI: −0.99, −0.35) and 12-month (MD = −0.67, 95%CI: −1.15, −0.19) follow-ups. …”

Expression of hereditary hemochromatosis C282Y HFE protein in HEK293 cells activates specific endoplasmic reticulum stress responses-5 by Matthew W Lawless (75792)

“…Treatment with TUDCA significantly increased -luc expression (#, = 0.0238) compared to WT HFE. Z A1AT transfection significantly decreased -luc expression **, = 0.0029 compared to WT HFE transfected with M A1AT. …”

How replay can hurt. by Georgy Antonov (11938961)

“…Such replay decreased the agent’s objective value function (as measured with respect to the true obtainable reward) of that state by 0.03 reward points (E). …”

Culture in the presence of RA increases <i>Sox10</i>, but EDN3 suppresses this effect. by Jonathan M. Gisser (456149)

“…Expression is normalized to β-actin and the -RA/-EDN3 condition was standardized to a value of 1. Solid lines denote a statistically significant difference (p<0.05) between “No RA” and “RA”, and broken lines indicate a p value >0.05. …”

Menstrual and Reproductive Factors and Risk of Gastric and Colorectal Cancer in Spain by Virginia Lope (740122)

“…</p><p>Results</p><p>Our results show an inverse association of age at first birth with gastric cancer risk (five-year trend: OR = 0.69; p-value = 0.006). Ever users of hormonal contraception presented a decreased risk of gastric (OR = 0.42; 95%CI = 0.26–0.69), colon (OR = 0.64; 95%CI = 0.48–0.86) and rectal cancer (OR = 0.61; 95%CI = 0.43–0.88). …”

Average viability of Group II BTICs (n = 3, ± SD). by Alice L. Yuan (5693012)

“…The combination of TMZ and ABT-888 significantly decreased viability in all BTICs (ns = p > 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001).…”